Zacks Research Issues Optimistic Outlook for MD Earnings

Pediatrix Medical Group, Inc. (NYSE:MD) – Stock analysts at Zacks Research lifted their Q1 2026 earnings estimates for Pediatrix Medical Group in a research report issued to clients and investors on Thursday, March 5th. Zacks Research analyst Team now anticipates that the company will earn $0.32 per share for the quarter, up from their prior estimate of $0.29. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Pediatrix Medical Group’s current full-year earnings is $1.38 per share. Zacks Research also issued estimates for Pediatrix Medical Group’s Q2 2026 earnings at $0.51 EPS, Q4 2026 earnings at $0.57 EPS, Q2 2027 earnings at $0.46 EPS and FY2028 earnings at $1.88 EPS.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The firm had revenue of $493.77 million for the quarter, compared to analyst estimates of $486.23 million. During the same period last year, the business earned $0.51 earnings per share. The firm’s quarterly revenue was down 1.7% compared to the same quarter last year.

MD has been the topic of a number of other reports. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. Truist Financial reduced their target price on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research report on Thursday, February 19th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research note on Friday, February 20th. Finally, UBS Group dropped their price objective on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.80.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $19.79 on Monday. The stock has a 50 day moving average of $21.11 and a two-hundred day moving average of $19.95. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.66. Pediatrix Medical Group has a 12 month low of $11.84 and a 12 month high of $24.99. The company has a market capitalization of $1.64 billion, a P/E ratio of 10.20 and a beta of 0.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC increased its holdings in Pediatrix Medical Group by 68,250.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock valued at $29,000 after purchasing an additional 1,365 shares in the last quarter. Transamerica Financial Advisors LLC bought a new stake in shares of Pediatrix Medical Group during the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pediatrix Medical Group in the fourth quarter valued at $33,000. Blue Trust Inc. acquired a new stake in shares of Pediatrix Medical Group in the fourth quarter valued at $37,000. Finally, TD Private Client Wealth LLC bought a new position in shares of Pediatrix Medical Group in the fourth quarter valued at about $39,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the transaction, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This trade represents a 7.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.90% of the stock is owned by corporate insiders.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.